​***If you're a T2B member and do not receive your confirmation within 1 business day of RSVPing (above), check your email spam folder. The automated Luma email includes the cal invite.***

​T2Bmeet pricing:

• ​Complimentary for T2B Pro and Student community members (log into your T2B account and access your promo code here)

• ​$50 for Basic members

​If you're not part of Ticket to Biotech, confirm you're eligible, and join before registering for this event:

​T2B Intake Form

​Hosted by Kura Oncology, this come-and-go networking event is open to all biopharma communicators in the T2B community. Complimentary refreshments will be provided.

​Come mix and mingle with fellow comms pros in San Diego. And while you're here, join our community give-back activity, in partnership with Life Science Cares.

​​See you there!

​

​About Our Host, Kura Oncology

​Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive BTD from the FDA for the treatment of relapsed/refractory (R/R) NPM1-m AML. In November 2024, Kura entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and the companies anticipate submission of a New Drug Application in the second quarter of 2025. Kura and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn.

​

​About Life Science Cares

​Life Science Cares (LSC) activates the financial and human capital of the life sciences industry and partners with nonprofits to disrupt the cycle of poverty and inequality in our communities. Now operating in five life science hubs (Boston, Philadelphia, San Diego, the San Francisco Bay Area and New York), LSC has invested $11.2 million and tens of thousands of volunteer hours in community organizations providing access to basic needs, access to education or access to opportunity. Learn more at https://lifesciencecares.org/.